|View printer-friendly version|
|November 21, 2004 5:22 p.m.|
|Teva Announces Tentative Approval Of Fosphenytoin Sodium Injection|
Jerusalem, Israel, November 21, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Fosphenytoin Sodium Injection USP, 50 mg PE/mL (PE = phenytoin sodium equivalents). Final approval is expected upon patent expiry on August 5, 2007.